RETRACTED: Adherence to treatment with oral antineoplastic therapy in outpatients

World Health Organization. Key facts, www.who.int/news-room/fact-sheets/detail/cancer (2018, accessed 19 January 2020).

National Instutue of Cancer. Types of cancer, www.inca.gov.br/tipos-de-cancer/cancer-de-mama (2019, accessed 19 January 2020).

Greer JA Amoyal N Nisotel L , et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist 2016; 21: 354–376.

Mohamed KEH Elamin A. Adherence to endocrine therapy and its relation to disease-free survival among breast cancer patients visiting an out-patient clinic at Khartoum oncology hospital, Sudan. J Eval Clin Pract 2020; 26: 1731–1743.

Birand N Boşnak AS Diker Ö , et al. The role of the pharmacist in improving medication beliefs and adherence in cancer patients. J Oncol Pharm Pract 2019; 25: 1916–1926.

Spencer JC Reeve BB Troester MA , et al. Factors associated with endocrine therapy non‐adherence in breast cancer survivors. Psycho‐Oncology 2020; 29: 647–654.

Stahlschmidt R Ferracini AC de Souza CM , et al. Adherence and quality of life in women with breast cancer being treated with oral hormone therapy. Support Care Cancer 2019; 27: 3799–3804.

Paranjpe R John G Trivedi M , et al. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat 2019; 174: 297–305.

Oliveira AD Filho Barreto JA Filho Neves SJF , et al. Relação entre a escala de adesão terapêutica de oito itens de morisky (MMAS-8) e o controle da pressão arterial. Arq Bras Cardiol 2012; 99: 649–658.

Nardin JM Schroth W Almeida TA , et al. The influences of adherence to tamoxifen and CYP2D6 pharmacogenetics on plasma concentrations of the active metabolite (Z) – endoxifen in breast cancer. Clin Transl Sci 2020; 13: 284–292.

Huguet F Cayuela JM Cambier N , et al. AdheRMC Investigators. Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice. Br J Haematol 2019; 187: 615–626.

Brazilian Society of Oncologic Surgery. Differences between CACON X UNACON, https://sbco.org.br/2015/04/04/diferencas-entre-cacon-x-unacon/#. :∼:text=Para%20o%20encaminhamento%20adequado%20do,exames%20que%20corroboram%20tal%20suspeita (2015, accessed 7 October 2020).

Ministry of Health. Law n 458 from 24 February 2017.

Ministry of Health. Law n 140 from 27 February 2014.

Coutinho LM Scazufca M Menezes PR. Methods for estimating prevalence ratios in cross-sectional studies. Rev Saude Publ 2008; 42: 992–998.

Guedes JBR Guerra MR Alvim MM , et al. Fatores associados à adesão e à persistência na hormonioterapia em mulheres com câncer de mama. Rev Bras Epidemiol 2017; 20: 636–649.

Fernández-Ribeiro F Olivera-Fernández R Crespo-Diz C. Adherence and safety study in patients on treatment with capecitabine. Farm Hosp 2017; 41: 204–221.

Muluneh B Deal A Alexander MD , et al. Patient perspectives on the barriers associated with medication adherence to oral chemotherapy. J Oncol Pharm Pract 2018; 24: 98–109.

Font R Espinas JA Barnadas A , et al. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain. Breast Cancer Res Treat 2019; 175: 733–740.

Sheppard VB He J Sutton A , et al. Adherence to adjuvant endocrine therapy in insured black and white breast cancer survivors: exploring adherence measures in patient data. J Manag Care Spec Pharm 2019; 25: 578–586.

Font R Espinas JA Gil-Gil M , et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer 2012; 107: 1249–1256.

Iacorossi L Gambalunga F De Domenico R , et al. Qualitative study of patients with metastatic prostate cancer to adherence of hormone therapy. Eur J Oncol Nurs 2019; 38: 8–12.

Krikorian S Pories S Tataronis G , et al. Adherence to oral chemotherapy: challenges and opportunities. J Oncol Pharm Pract 2019; 25: 1590–1598.

Andrzejevski VMS. Fatores que podem influenciar na adesão aos antineoplásicos orais. Master’s Thesis, Federal University of Paraná, BR, 2016.

Bhattacharya D Easthall C Willoughby KA , et al. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract 2012; 18: 333–342.

Gomes e Martins A Chavaglia SRR Ohl RIB , et al. Adesão ao tratamento clínico ambulatorial da hipertensão arterial sistêmica. Acta Paul Enferm 2014; 27: 266–272.

Ferreira MA Iwamoto HH. Determinantes da adesão ao tratamento de usuários com hipertensão cadastrados no programa hiperdia da atenção primária à saúde. REME 2017; 21: e1037.

Silva AG Azevedo C da Mata LRF , et al. Adesão de pacientes ao tratamento com antineoplásicos orais: fatores influentes. Rev Baiana Enferm 2017; 31: e16428.

Dos Anjos ACY Zago MMF. Ressignificação da vida do cuidador do paciente idoso com câncer. Rev Bras Enferm Rev Bras Enferm 2014; 67: 752–758.

Sedjo RL Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 2011; 125: 191–200.

Mathes T Pieper D Antoine SL , et al. Adherence influencing factors in patients taking oral anticancer agents: a systematic review. Cancer Epidemiol 2014; 38: 214–226.

Brito C Portela MC de Vasconcellos MT. Adherence to hormone therapy among women with breast cancer. BMC Cancer 2014; 14: 397.

Larizza MA Dooley MJ Stewart K , et al. Factors influencing adherence to molecular therapies in haematology‐oncology outpatients. J Pharm Pract Res 2006; 36: 115–118.

Verbrugghe M Duprez V Beeckman D , et al. Factors influencing adherence in cancer patients taking oral tyrosine kinase inhibitors. Cancer Nurs 2016; 39: 153–162.